Skip to main content
PFE
NYSE Life Sciences

Blackstone to Fund Up to $1.5B of Pfizer's Monthly GLP-1 Obesity Drug Through 2028

Tom Rudovsky · Reported by BusinessWire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$29.45
Mkt Cap
$167.861B
52W Low
$23.62
52W High
$31.44
52W Position info
25% above low
Off High info
6.3% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

PFE sits 25% above its 52-week low of $23.62.

Summary

Blackstone Life Sciences will pay up to $1.5 billion of development costs through 2028 for berobenatide, Pfizer's investigational monthly GLP-1 peptide for chronic weight management. Pfizer keeps full operational control and Blackstone gets no ownership in the drug; instead it earns milestone payments tied to US approval of monthly dosing and to commercial sales thresholds. The structure offloads a chunk of the obesity program's spend while keeping the upside in-house, which matters given the pipeline load: Pfizer plans 20+ obesity trials in 2026, including 10 Phase 3 studies of berobenatide. This builds on the Metsera acquisition that brought PF-3944 into the fold and follows the November 3rd guidance raise to $62.0-64.0 billion in revenue. The key question is whether berobenatide's monthly dosing holds up in Phase 3 and clears regulators, since the Blackstone payouts hinge on that approval and on sales milestones.

At the time of this announcement, PFE was trading at $29.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $167.9B. The 52-week trading range was $23.62 to $31.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $29.49 info
Change: -$1.17 (-4%) info
Market Cap: $167.861B info
PFE
Nov 03, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.62
Real-time Price: $29.49 info
Change: -$1.13 (-4%) info
Market Cap: $167.861B info
PFE
Nov 03, 2026, 6:55 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $30.73
Real-time Price: $29.49 info
Change: -$1.24 (-4%) info
Market Cap: $167.861B info
PFE
Nov 03, 2026, 6:45 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.98
Real-time Price: $29.49 info
Change: -$1.49 (-5%) info
Market Cap: $167.861B info
PFE
Oct 27, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.77
Real-time Price: $29.49 info
Change: -$0.2777 (-0.93%) info
Market Cap: $167.861B info